Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, May 1998, p. 1222-1228, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Risk of Development of In Vitro Resistance to
Amoxicillin, Clarithromycin, and Metronidazole in
Helicobacter pylori
Mikael
Sörberg,1,*
Håkan
Hanberger,2
Maud
Nilsson,3
Anders
Björkman,1 and
Lennart E.
Nilsson3
Department of Infectious Diseases, Danderyd
Hospital, S-182 88 Danderyd,1 and
Infectious Diseases2 and
Department of Clinical Microbiology,3
University Hospital, S-581 85 Linköping, Sweden
Received 11 August 1997/Returned for modification 3 December
1997/Accepted 12 February 1998
 |
ABSTRACT |
We have studied initial killing, morphological alterations, the
frequency of occurrence, and the selective growth of resistant subpopulations of Helicobacter pylori during exposure to
amoxicillin, clarithromycin, or metronidazole by bioluminescence assay
of intracellular ATP levels, microscopy, and a viable count assay. We
found an induction of spheroplasts and a decrease in intracellular ATP levels after 21 h of exposure to high concentrations of
amoxicillin. During clarithromycin exposure the onset of a decrease in
intracellular ATP levels started after prolonged incubation, and with
the highest concentration of clarithromycin an induction of coccoid
forms was seen after 68 h. Metronidazole exposure resulted in the
strongest initial decrease in intracellular ATP levels, and coccoid
forms were seen after 21 h of exposure to high concentrations of
metronidazole. Amoxicillin caused a low-level increase in resistant
subpopulations, which indicates a need for surveillance of the
amoxicillin susceptibility of H. pylori in order to detect
decreasing susceptibility. No increase in the numbers of resistant
subpopulations was demonstrated during clarithromycin exposure.
Metronidazole selected resistant subpopulations, which caused
high-level resistance in H. pylori.
 |
INTRODUCTION |
Helicobacter pylori
infection is a principal cause of chronic gastritis type B
(13) and is associated with gastric cancer (19, 20,
33). Eradication of H. pylori prevents relapse of
duodenal ulcer, and treatment of this infection has now become standard
for patients with peptic ulcer disease (22, 37). The regimen
most widely used today to eradicate H. pylori is combination therapy with two antibiotics and bismuth (17, 27) or an acid pump inhibitor (3, 22). A major reason for H. pylori eradication failure is resistance to metronidazole (4,
5, 9, 17, 27, 29, 34, 36) or clarithromycin (11, 44).
In contrast, H. pylori does not appear to develop resistance
to amoxicillin (16). The prevalence of primary metronidazole
resistance varies between 7 and 90% (2, 9, 14, 36), with
the highest prevalences occurring in people from developing countries
(2, 9, 14), after previous metronidazole ingestion (2,
14), and in women (2, 14, 36). The prevalence of
primary clarithromycin resistance is between 4 and 7% (12, 16,
45). The development of resistance during therapy has been
observed for both metronidazole (35, 36, 46) and
clarithromycin (11, 26, 43).
The aim of this study was to evaluate the initial killing,
morphological alterations, and the frequency of occurrence and the
selective growth of resistant subpopulations of H. pylori during exposure to amoxicillin, clarithromycin, or metronidazole.
 |
MATERIALS AND METHODS |
Bacterial strain.
H. pylori NCTC 11637 was used in the
present study.
Antibiotics.
Amoxicillin and metronidazole were purchased
from Sigma Chemical Co., St. Louis, Mo. Clarithromycin was kindly
provided by Abbott Laboratories, Chicago, Ill.
Growth medium.
Mueller-Hinton broth (MHB; Gibco Limited,
Renfrewshire, Scotland) supplemented with 50 mg of Ca2+ per
liter, 25 mg of Mg2+ per liter, and 1% fetal calf serum
was used as the growth medium.
Bioluminescence assay of intracellular ATP levels.
A
100-µl sample from the bacterial culture was incubated at 37°C for
10 min with 100 µl of the ATP-hydrolyzing enzyme apyrase, purified
grade I (Sigma Chemical Co.) in supplemented MHB, to eliminate
extracellular ATP. A 50-µl sample of the apyrase-treated sample was
pipetted into 500 µl of boiling 0.1 M Tris buffer (pH 7.75)
containing 2 mM EDTA to release the intracellular ATP and inactivate
the apyrase. After being heated for 90 s, the extracts were cooled
before the intracellular ATP levels were assayed. This extraction was
performed in an LKB Biocal 2030 incubator (LKB Products, Bromma,
Sweden). Luciferase reagent (100 µl) was added to 550 µl of each
cooled extract, and the light intensity was measured in a 1250 Luminometer (LKB Wallac, Turku, Finland) and was recorded on a 1250 Display (LKB Wallac). An ATP-monitoring reagent (Bio Orbit, Turku,
Finland) was used in the assay of ATP levels. The ATP levels in the
samples were calculated by using the results of assays of standard
amounts of ATP as a reference. A correction was made for background
luminescence. Extracts to which known amounts of ATP were added were
used as internal standards in order to correct for inhibition of the
luciferase reaction by the reagents. The coefficient of variation for
the bioluminescence assay has been shown to vary between 1.7 and 6.5%
(41).
Monitoring of bacterial growth during antibiotic exposure in
broth.
The bacterial numbers were determined by the
bioluminescence assay of bacterial ATP levels. As indicated by Thore et
al. (42) and Molin et al. (30), 10
6
M ATP corresponded to approximately 109 bacteria/ml. From a
culture with bacteria in the log phase diluted to 107
CFU/ml, 5 ml was transferred to 50-ml Erlenmeyer flasks containing 50 µl of antibiotics at different concentrations. The concentrations tested were as follows: amoxicillin, 0.0005 to 0.25 µg/ml;
clarithromycin, 0.0005 to 0.25 µg/ml; and metronidazole, 0.06 to 32 µg/ml. Samples were taken daily for bioluminescence assay of
intracellular bacterial ATP levels. The flasks were incubated at 37°C
under microaerobic conditions (5% oxygen, 10% carbon dioxide, 85%
nitrogen) in an incubator box (ASSAB with CO2 and
O2 regulator; Kebo Biomed, Spånga, Sweden). The
experiments were repeated three times.
Morphology.
The bacteria were exposed to amoxicillin,
clarithromycin, and metronidazole and were studied by light microscopy
at a magnification of ×1,250 after being stained with acridine orange
(28). The sensitivity of the staining method is
104 CFU/ml (28).
Population analysis.
Population analyses were performed with
control cultures and regrowing cultures exposed to metronidazole or
amoxicillin. Population analyses were also performed with cultures that
grew in the presence of the highest concentration during clarithromycin
exposure. The contents of the flasks were thoroughly mixed, and 0.1-ml
portions were removed and diluted serially in 0.9-ml aliquots of
phosphate-buffered saline. A total of 50 µl from each dilution was
dropped onto paper disc method (PDM) agar plus 5% defibrinated horse
blood (AB Biodisk, Solna, Sweden) containing different concentrations
of amoxicillin (0.0005 to 0.25 µg/ml), clarithromycin (0.0005 to 0.25 µg/ml), and metronidazole (0.06 to 32 µg/ml). The drops were
allowed to dry at room temperature. The plates were incubated for 5 days at 37°C under microaerobic conditions, and the colonies were
then counted. The frequencies of occurrence of variants resistant to different concentrations of amoxicillin, clarithromycin, and
metronidazole were calculated by dividing the number of colonies on
plates with antibiotic by the number of colonies on plates without
antibiotic. The experiments were repeated three times. Ten passages of
the metronidazole-resistant cultures were done in drug-free MHB.
Susceptibility testing on agar plates was done with passaged cultures
in antibiotic-free broth by the E-test (AB Biodisk).
Determination of antibiotic concentrations in H. pylori cultures.
Samples from H. pylori cultures
exposed to 0.25 µg of amoxicillin per ml, 0.25 µg of clarithromycin
per ml, or 32 µg of metronidazole per ml were taken after 0, 21, 46, 68, 96, 118, 142, 166, 191, 214, and 267 h incubation at 37°C
under microaerobic conditions. The samples were put in wells of a PDM
agar (AB Biodisk) tray with Micrococcus luteus ATCC 9341 for
determination of amoxicillin and clarithromycin concentrations and in
wells of a PDM agar plus 5% defibrinated horse blood (AB Biodisk,
Solna, Sweden) tray with Clostridium perfingens ATCC 13124 for determination of metronidazole concentration. The trays with
M. luteus were incubated overnight under aerobic conditions,
and the trays with C. perfringens were incubated overnight
under anaerobic conditions. The resulting inhibition zones surrounding
the wells were measured and were compared with those obtained by linear
regression analysis with standard concentrations of drugs.
 |
RESULTS |
Growth and morphology of H. pylori during exposure to
amoxicillin.
Growth of the cultures with an inoculum of 1.9 × 10
8 M ATP was monitored, and three growth patterns
were seen. Intracellular ATP levels increased in the cultures exposed
to low concentrations of amoxicillin (
0.004 µg/ml) (Fig.
1). There was an initial growth inhibition in the cultures exposed to 0.008 µg of amoxicillin per ml
(Fig. 1). The cultures exposed to
0.015 µg of amoxicillin per ml
showed an initial decrease in intracellular ATP levels after 46 h
(Fig. 1). Microscopy showed spheroplasts in cultures in which a
decrease in intracellular ATP levels occurred. After 118 h a few
bacillary forms were seen, and the numbers of these forms increased
when the intracellular ATP level in these cultures increased. There was
no decrease in the amoxicillin concentration in the broth cultures
containing 0.008 and 0.015 µg of amoxicillin per ml when regrowth
occurred. In the culture exposed to 0.03 µg of amoxicillin per ml,
intracellular ATP levels increased after 191 h, and microscopy
showed a mixed population of bacillary forms, spheroplasts, and coccoid
cells. In this culture there was a reduction in the amoxicillin
concentration, and at 191 h, when the culture regrew, only 50% of
the initial amoxicillin concentration was left in the broth. At
concentrations above 0.03 µg of amoxicillin per ml there was no
regrowth.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 1.
Monitoring of growth of H. pylori assayed by
bioluminescence assay of ATP levels in bacteria in an unexposed culture
( ) and cultures exposed to amoxicillin at 0.008 ( ), 0.015 (*),
0.03 ( ), and 0.25 ( ) µg/ml.
|
|
Population analyses of cultures exposed to amoxicillin.
Population analyses were performed with the unexposed cultures and
cultures exposed to amoxicillin at concentrations of 0.008, 0.015, and
0.03 µg/ml. The bacteria in the unexposed cultures were resistant to
up to 0.008 µg/ml (Fig. 2). At higher
concentrations on agar plates there was a reduction in the frequency of
resistant variants for the unexposed broth cultures (Fig. 2). The
cultures exposed to 0.008 and 0.015 µg of amoxicillin per ml in broth
were resistant to up to 0.015 µg/ml, and the frequency of resistant variants exposed to amoxicillin at 0.03 µg/ml was 10
1
(Fig. 2). The frequency of resistant variants in the cultures exposed
to 0.03 µg of amoxicillin per ml was lower than that for the
unexposed cultures (Fig. 2). Population analyses were performed with
the control cultures on two different occasions with an interval of 3 days, and no reduction in the amoxicillin concentrations on the agar
plates was found.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 2.
Population analysis of H. pylori in unexposed
cultures ( and ) and cultures exposed to amoxicillin at 0.008 ( ), 0.015 (*) and 0.03 ( ) µg/ml.
|
|
Growth and morphology of H. pylori during exposure to
clarithromycin.
Growth of the cultures with an inoculum of
2.3 × 10
8 M ATP was monitored. Intracellular ATP
levels increased in the cultures exposed to low concentrations of
clarithromycin (
0.06 µg/ml) (Fig. 3).
There was a concentration-dependent inhibition of the increase in
intracellular ATP levels, and after prolonged incubation there was a
concentration-dependent decrease in intracellular ATP levels in the
cultures (Fig. 3). Microscopy showed bacillary forms in the growing
cultures, and a conversion from bacillary to coccoid forms was seen
when the intracellular ATP levels decreased. No cultures showed
regrowth. The clarithromycin concentrations in broth were stable
throughout the experiment.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
Monitoring of growth of H. pylori assayed by
bioluminescence assay of ATP levels in bacteria in an unexposed culture
( ) and cultures exposed to clarithromycin at 0.008 to 0.25 µg/ml
( , 0.250 µg/ml; , 0.125 µg/ml; , 0.060 µg/ml; , 0.030 µg/ml; *, 0.015 µg/ml; , 0.008 µg/ml).
|
|
Population analyses of cultures exposed to clarithromycin.
Population analyses were performed with the unexposed cultures and
cultures exposed to clarithromycin at concentrations of 0.015 and 0.008 µg/ml. The unexposed cultures and the cultures exposed to 0.008 µg
of clarithromycin per ml were resistant to up to 0.015 µg/ml (Fig.
4). At higher concentrations there was a
reduction in the frequency of resistant variants to 10
1
after exposure to clarithromycin at 0.03 µg/ml (Fig. 4). For cultures
exposed to 0.015 µg of clarithromycin per ml the frequency of
resistant variants was lower after exposure to clarithromycin at 0.015 and 0.03 µg/ml than that for the unexposed cultures and the cultures
exposed to 0.008 µg of clarithromycin per ml (Fig. 4). Population
analyses were performed with the control cultures on two different
occasions with an interval of 3 days, and no reduction in the
clarithromycin concentration in the agar plates was found.

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 4.
Population analysis of H. pylori in unexposed
cultures ( and ) and cultures exposed to clarithromycin at 0.008 ( ) and 0.015 (*) µg/ml. 5E-04, 0.0005.
|
|
Growth and morphology of H. pylori during exposure to
metronidazole.
Growth of the cultures with an inoculum of 1.9 × 10
8 M ATP was monitored, and two growth patterns were
seen. Intracellular ATP levels increased in the cultures exposed to low
concentrations of metronidazole (
0.5 µg/ml) (Fig.
5). The cultures exposed to 1 to 32 µg
of metronidazole per ml showed an initial decrease in intracellular ATP
levels (Fig. 5), and microscopy showed a conversion from bacillary to
coccoid forms after 21 h. When the intracellular ATP levels
increased in the cultures exposed to 1 to 4 µg of metronidazole per
ml, a change in morphology was seen by microscopy, from coccoid forms
to bacillary forms. In cultures with concentrations above 4 µg of
metronidazole per ml there was no regrowth (Fig. 5). The metronidazole
concentrations in broth were stable throughout the experiment.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 5.
Monitoring of growth of H. pylori assayed by
bioluminescence assay of ATP levels in bacteria in an unexposed culture
( ) and cultures exposed to metronidazole at 0.5 to 4 and 32 µg/ml
( , 32 µg/ml; , 4 µg/ml; *, 2 µg/ml; , 1 µg/ml; ,
0.5 µg/ml).
|
|
Population analyses of cultures exposed to metronidazole.
Population analyses were performed with the unexposed cultures and
cultures exposed to metronidazole at concentrations of 1 to 4 µg/ml.
The bacteria in the unexposed cultures were resistant to up to 0.25 µg/ml (Fig. 6). With higher
concentrations there was a reduction in the frequency of resistant
variants for the unexposed cultures (Fig. 6). For the cultures exposed
to 1 to 4 µg of metronidazole per ml, resistant variants were
resistant to up to 32 µg/ml (Fig. 6). The selection of resistant
variants was concentration dependent, and after exposure to the highest concentration (4 µg of metronidazole per ml) all bacteria in the population were resistant to metronidazole at 32 µg/ml (Fig. 6). Population analyses were performed with the control cultures on three
different occasions with a total interval of 13 days, and no reduction
in the metronidazole concentrations on the agar plates was found (Fig.
6). The resistance remained stable through 10 passages in MHB for all
cultures in which metronidazole resistance developed.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 6.
Population analysis of H. pylori in an
unexposed cultures ( , , and ) and cultures exposed to
metronidazole at 1 to 4 µg/ml ( , 1 µg/ml; *, 2 µg/ml; , 4 µg/ml).
|
|
 |
DISCUSSION |
This study showed an initial decrease in intracellular ATP levels
during exposure of H. pylori to high concentrations of
amoxicillin (Fig. 1), and this bactericidal effect of amoxicillin is in
agreement with the effect found in a study by Berry et al.
(6). During exposure of H. pylori to amoxicillin,
microscopy showed spheroplasts after 21 h, which is in accordance
with the findings of a study by Nilius et al. (32) and a
previous study by us (40), in which we found a
concentration-dependent induction of spheroplasts after only 2 h.
Other investigators have reported a morphologic conversion of H. pylori during exposure to amoxicillin but have not distinguished
between coccoid forms and spheroplasts (6, 7). Armstrong et
al. (1) reported central clearing and vesiculation of
H. pylori after a 24-h exposure to amoxicillin but did not discuss these findings in terms of coccoid forms or spheroplasts. No
reports on the clinical significance of amoxicillin resistance in
H. pylori have been published, and Glupczynski et al.
(16) found an unchanged susceptibility of H. pylori to amoxicillin over a 5-year period. We found a small
increase in the numbers of resistant subpopulations in all except one
of the regrowing cultures exposed to amoxicillin. In one culture
(containing 0.03 µg of amoxicillin per ml), regrowth occurred after
191 h due to a decrease in the concentration of amoxicillin in the
broth (Fig. 2). Our results are in agreement with those of Haas et al.
(18), who found increased amoxicillin MICs during exposure
to amoxicillin in several passages. Our results and those of Haas et
al. (18) indicate that there is a need for surveillance of
the amoxicillin susceptibility of H. pylori in order to
detect decreasing levels of susceptibility.
After a prolonged incubation, clarithromycin exposure resulted in a
concentration-dependent decrease in intracellular ATP levels in
H. pylori cultures (Fig. 3). Similar results were found by
Flamm et al. (15), who demonstrated a bactericidal effect of
clarithromycin on H. pylori after 8 h of exposure to
clarithromycin. In an earlier study (40) we could not find
any bactericidal effect after 5 h of exposure of H. pylori to clarithromycin, but this was probably due to a shorter
exposure time. A conversion from bacillary to coccoid forms was seen in
this study after 68 h of exposure of H. pylori to the
highest concentration of clarithromycin. After the same exposure time,
Nilius et al. (32) found an induction of coccoid forms
during exposure of H. pylori to erythromycin. We found no
regrowth or increase in the numbers of resistant subpopulations of
H. pylori during clarithromycin exposure (Fig. 4). Haas et al. (18) found variation among different strains, with
increasing MICs for H. pylori during exposure to
erythromycin. This variation among different strains might explain why
we did not find resistant subpopulations of the strain used in our
study.
The strongest initial decrease in intracellular ATP levels was seen
during exposure of H. pylori to metronidazole (Fig. 5), and
this bactericidal effect of metronidazole on H. pylori has also been demonstrated by Armstrong et al. (1). We found a conversion from bacillary to coccoid forms after 21 h in the
cultures in which a decrease in intracellular ATP levels occurred. This is similar to the results of a study by Armstrong et al.
(1), who reported a conversion to coccoid forms after
48 h of exposure of H. pylori to metronidazole. The
mechanisms for metronidazole resistance are probably a decreased
ability of metronidazole-resistant strains to achieve a sufficiently
low redox potential under microaerobic conditions for the necessary
reduction of metronidazole and that during short periods of anaerobic
conditions these strains manage to reduce and store sufficient amounts
of metronidazole so as to appear fully susceptible after subsequent
incubation under microaerobic conditions (8, 38, 48). This
leads to a slower uptake of metronidazole by resistant strains of
H. pylori than by sensitive strains, which has been reported
by several investigators (25, 31, 38). We found selection
and regrowth of resistant subpopulations of H. pylori in all
regrowing cultures during exposure to metronidazole (Fig. 6). During
this regrowth a change in morphology from coccoid to bacillary forms
was seen by microscopy. This change is probably due to a low frequency
of occurrence of resistant subpopulations rather than a conversion from
coccoid to bacillary forms. This caused a decreased susceptibility to
metronidazole, which is in agreement with the findings of Haas et al.
(18), who reported an increase in the MIC of metronidazole
for H. pylori after several passages during exposure to
metronidazole. When evaluating the development of resistance to
metronidazole during treatment, it is important to study whether there
is a selection of spontaneous resistant variants of the infecting
strain or whether there is reinfection with an exogenous strain
(23, 35). The metronidazole resistance in our study was
stable during 10 passages, which is in agreement with the findings of a
study by Haas et al. (18), but there have also been reports
of unstable metronidazole resistance. Zwet et al. (48) found
that metronidazole resistance induced in vitro was reversed in 30% of
the isolates by further culture on antibiotic-free plates. The
different results concerning the stability of metronidazole resistance
might be explained by methodological differences such as the use of
different inocula (21) and by the use of different
incubation conditions (8, 38, 47).
When studying the morphology of H. pylori it is important to
differentiate between coccoid cells (1, 6) and spheroplasts (32). In our earlier study we found a rapid induction of
spheroplasts during exposure of H. pylori to amoxicillin
(40), while the rate of conversion to coccoid forms during
exposure to clarithromycin and metronidazole in this study was slower.
The spheroplasts are larger than the coccoid forms seen by microscopy
(unpublished results). The coccoid forms changed color, from orange to
green, during prolonged exposure to clarithromycin and metronidazole when acridine orange staining was used (unpublished results). A cell
containing more RNA than DNA stains orange, and a cell in which much of
the RNA has been degraded but still retains its DNA stains green
(24). The degradation of RNA has been correlated with a loss
of viability (10). The spheroplasts stained orange (unpublished results), and we found in an earlier study (40) that they reverted to bacillary forms. In another previous study (39) we found a low ATP level in the coccoid cell during
prolonged incubation of H. pylori, but we were not able to
demonstrate a conversion to bacillary forms.
In conclusion, we found an induction of spheroplasts and a decrease in
intracellular ATP levels after 21 h of exposure of H. pylori to high concentrations of amoxicillin. During
clarithromycin exposure the onset of the decrease in intracellular ATP
levels started after prolonged incubation, and with the highest
concentration of clarithromycin an induction of coccoid forms was seen
after 68 h. Metronidazole exposure resulted in the strongest
initial decrease in intracellular ATP levels, and coccoid forms were
seen after 21 h of exposure to high concentrations of
metronidazole. Amoxicillin caused a low-level increase in the numbers
of resistant subpopulations, which indicates that there is a need for
surveillance of the amoxicillin susceptibility of H. pylori
in order to detect decreasing susceptibility. No increase in resistant
subpopulations was demonstrated during clarithromycin exposure.
Metronidazole selected resistant subpopulations, which caused
high-level resistance in H. pylori.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Infectious Diseases, Danderyd Hospital, S-182 88 Danderyd, Sweden.
Phone: 468 655 6025. Fax: 468 755 12 37. E-mail:
Mikael.Sorberg{at}kids.ki.se.
 |
REFERENCES |
| 1.
|
Armstrong, J. A.,
S. H. Wee,
C. S. Goodwin, and D. H. Wilson.
1987.
Response of Campylobacter pyloris to antibiotics, bismuth and an acid-reducing agent an ultrastructural study.
J. Med. Microbiol.
24:343-350[Abstract/Free Full Text].
|
| 2.
|
Banatvala, N.,
G. R. Davies,
Y. Abdi,
A. Clements,
D. S. Rampton,
J. M. Hardie, and R. A. Feldman.
1994.
High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease.
Gut
35:1562-1566[Abstract/Free Full Text].
|
| 3.
|
Bazzoli, F.,
R. M. Zagari,
S. Fossi,
P. Pozzato,
G. Alampi,
P. Simoni,
S. Sottili,
A. Roda, and E. Roda.
1994.
Short-term low-dose triple therapy for the eradication of Helicobacter pylori.
Eur. J. Gastroenterol. Hepatol.
6:773-777.
|
| 4.
|
Bell, G. D.,
K. Powell,
S. M. Burridge,
A. F. Bowden,
W. Atoyebi,
G. H. Bolton,
P. H. Jones, and C. Browns.
1995.
Rapid eradication of Helicobacter pylori infection.
Aliment. Pharmacol. Ther.
9:41-46[Medline].
|
| 5.
|
Bell, G. D.,
K. Powell,
S. M. Burridge,
A. Pallecaros,
P. H. Jones,
P. W. Gant,
G. Harrison, and J. E. Trowell.
1992.
Experience with "triple" anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance.
Aliment. Pharmacol. Ther.
6:427-435[Medline].
|
| 6.
|
Berry, V.,
K. Jennings, and G. Woodnutt.
1995.
Bacteriocidal and morphological effect of amoxicillin on Helicobacter pylori.
Antimicrob. Agents Chemother.
39:1859-1861[Abstract].
|
| 7.
|
Bode, G.,
F. Mauch, and P. Malfertheiner.
1993.
The coccoid form of Helicobacter pylori. Criteria for their viability.
Epidemiol. Infect.
111:483-490[Medline].
|
| 8.
|
Cederbrant, G.,
G. Kahlmeter, and Å. Ljungh.
1992.
Proposed mechanism for metronidazole resistance in Helicobacter pylori.
J. Antimicrob. Chemother.
29:115-120[Abstract/Free Full Text].
|
| 9.
|
Ching, C. K.,
K. P. Leung,
R. W. Yung,
S. K. Lam,
B. C. Wong,
K. C. Lai, and C. L. Lai.
1996.
Prevalence of metronidazole resistance Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong.
Gut
38:675-678[Abstract/Free Full Text].
|
| 10.
|
Davis, B. D.,
S. J. Lager, and P. C. Tai.
1986.
Role of ribosome degradation in the death of starved Escherichia coli cells.
J. Bacteriol.
166:439-445[Abstract/Free Full Text].
|
| 11.
|
Debets-Ossenkopp, Y. J.,
M. Sparrius,
J. G. Kusters,
J. J. Kolkman, and C. M. Vandenbroucccke-Grauls.
1996.
Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori.
FEMS Microbiol. Lett.
142:37-42[Medline].
|
| 12.
| De Koster, E., A. Cozzoli, C. Jonas, R. Ntounda, J. P. Butzler, and M. Detenre. 1996. Six years resistance of
Helicobacter pylori to macrolides and imidazoles. Gut
39(Suppl. 2):A5. (Abstract 1A:04.)
|
| 13.
| Dixon, M. F., and G. M. Sobala. 1992. Gastritis and duodenitis: histopathological spectrum. Eur. J. Gastroenterol. Hepatol. 4(Suppl. 2):17-23.
|
| 14.
|
European Study Group on Antibiotic Susceptibility of Helicobacter pylori.
1992.
Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori.
Eur. J. Microbiol. Infect. Dis.
11:777-781.
|
| 15.
|
Flamm, R. K.,
J. Beyer,
S. K. Tanaka, and J. Clement.
1996.
Kill kinetics of antimicrobial agents against Helicobacter pylori.
J. Antimicrob. Chemother.
38:719-725[Abstract/Free Full Text].
|
| 16.
| Glupczynski, Y., S. Goutier, C. van den Borre, J. P. Butzler, and A. Burette. 1995. Surveillance of
Helicobacter pylori resistance to antimicrobial agents in
Belgium from 1989 to 1994. Gut 37(Suppl. 1):A56.
(Abstract 223.)
|
| 17.
|
Graham, D. Y.,
G. M. Lew,
H. M. Malaty,
D. Evans,
P. Klein, and L. Alpert.
1992.
Factors influencing the eradication of Helicobacter pylori with triple therapy.
Gastroenterology
102:493-496[Medline].
|
| 18.
|
Haas, C. E.,
D. E. Nix, and J. J. Schentag.
1990.
In vitro selection of resistant Helicobacter pylori.
Antimicrob. Agents Chemother.
34:1637-1641[Abstract/Free Full Text].
|
| 19.
|
Hansson, L. E.,
L. Engstrand,
O. Nyren,
D. J. Evans,
A. Lindgren, and R. Bergström.
1993.
Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma.
Gastroenterology
105:1098-1103[Medline].
|
| 20.
|
Hansson, L. E.,
L. Engstrand,
O. Nyren, and A. Lindgren.
1995.
Prevalence of Helicobacter pylori infection in subtypes of gastric cancer.
Gastroenterology
109:885-888[Medline].
|
| 21.
|
Henriksen, T. H.,
Ö. Brorson,
R. Schöyen, and T. Thoresen.
1996.
Risks related to lack of standardization of tests to detect in vitro metronidazole resistance in Helicobacter pylori.
Eur. J. Microbiol. Infect. Dis.
15:484-488.
|
| 22.
|
Hentchel, E.,
G. Brandsätter,
B. Dragosics,
A. M. Hirschl,
H. Nemec, and K. Schutze.
1993.
Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and recurrence of duodenal ulcer.
N. Engl. J. Med.
328:308-312[Abstract/Free Full Text].
|
| 23.
|
Jorgensen, M.,
G. Daskalopoulos,
V. Warburton,
H. M. Mitchell, and S. L. Hazell.
1996.
Multiple strain colonization and metronidazole resistance in Helicobacter pylori-infected patients: identification from sequential and multiple biopsy specimens.
J. Infect. Dis.
174:631-635[Medline].
|
| 24.
|
Kasten, F. H.
1967.
Cytochemical studies with acridine orange and the influence of dye contaminants in staining of nucleic acid.
Int. Rev. Cytol.
21:141-202[Medline].
|
| 25.
|
Lacey, S. L.,
S. F. Moss, and G. W. Taylor.
1993.
Metronidazole uptake by sensitive and resistant isolates of Helicobacter pylori.
J. Antimicrob. Chemother.
32:393-400[Abstract/Free Full Text].
|
| 26.
|
Logan, R. P.,
P. A. Gummet,
H. D. Schaufelberger,
R. R. Greaves,
G. M. Mendelson, and M. M. Walker.
1994.
Eradication of Helicobacter pylori with clarithromycin and omeprazole.
Gut
35:323-326[Abstract/Free Full Text].
|
| 27.
|
Logan, R. P.,
P. A. Gummet,
J. J. Misiewicz,
Q. N. Karim,
M. M. Walker, and J. H. Baron.
1991.
One week eradication regimen for Helicobacter pylori.
Lancet
338:1249-1252[Medline].
|
| 28.
|
McCarthy, L. R., and J. E. Senne.
1980.
Evaluation of acridine orange stain for detection of microorganisms in blood cultures.
J. Clin. Microbiol.
11:281-285[Abstract/Free Full Text].
|
| 29.
|
Midola, P. H.,
J. R. Lambert, and J. Turnidge.
1996.
Metronidazole resistance: a predictor of failure of Helicobacter pylori eradication by triple therapy.
J. Gastroenterol. Hepatol.
11:290-292[Medline].
|
| 30.
|
Molin, Ö.,
L. Nilsson, and S. Ånsehn.
1983.
Rapid detection of bacterial growth in blood cultures by bioluminescent assay of bacterial ATP.
J. Clin. Microbiol.
18:521-525[Abstract/Free Full Text].
|
| 31.
|
Moore, R. A.,
B. Beckthold, and L. E. Bryan.
1995.
Metronidazole uptake in Helicobacter pylori.
Can. J. Microbiol.
41:746-749[Medline].
|
| 32.
|
Nilius, M.,
A. Ströhle,
G. Bode, and P. Malfertheiner.
1993.
Coccoid like form(CLF) of Helicobacter pylori. Enzyme activity and antigenicity.
Zentralbl. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt. 1 Orig.
280:259-272.
|
| 33.
|
Passonet, J.,
G. D. Freidman, and D. P. Vandersteed.
1991.
Helicobacter pylori infection and the risk of gastric carcinoma.
N. Engl. J. Med.
325:1127-1131[Abstract].
|
| 34.
|
Powell, K. U.,
G. D. Bell,
A. F. Bowden,
J. E. Trowell, and P. H. Jones.
1995.
An effective one-week Helicobacter pylori eradication therapy using omeprazole, clarithromycin and metronidazole.
Br. J. Clin. Res.
6:85-90.
|
| 35.
|
Rautelin, H.,
W. Tee,
K. Seppälä, and T. U. Kosunen.
1994.
Ribotyping patterns and emergence of metronidazole resistance in paired clinical samples of Helicobacter pylori.
J. Clin. Microbiol.
32:1079-1082[Abstract/Free Full Text].
|
| 36.
|
Rautelin, H.,
K. Seppälä,
O.-V. Renkonen,
U. Vainio, and T. U. Kosunen.
1992.
Role of metronidazole resistance in therapy of Helicobacter pylori infection.
J. Antimicrob. Chemother.
36:163-166.
|
| 37.
|
Rauws, E. A., and G. N. Tytgat.
1990.
Cure of duodenal ulcer associated with eradication of Helicobacter pylori.
Lancet
335:1233-1235[Medline].
|
| 38.
|
Smith, M. R., and D. I. Edwards.
1995.
The influence of microaerophilia and anaerobiosis on metronidazole uptake in Helicobacter pylori.
J. Antimicrob. Chemother.
36:453-461[Abstract/Free Full Text].
|
| 39.
|
Sörberg, M.,
M. Nilsson, and L. E. Nilsson.
1996.
Morphologic conversion of Helicobacter pylori from bacillary form to coccoid form evaluated by bioluminescence, microscopy and viable count.
Eur. J. Microbiol. Infect. Dis.
15:216-219.
|
| 40.
|
Sörberg, M.,
M. Nilsson,
H. Hanberger, and L. E. Nilsson.
1997.
Pharmacodynamic effects of antibiotics and acid pump inhibitors on Helicobacter pylori.
Antimicrob. Agents Chemother.
41:2218-2223[Abstract].
|
| 41.
|
Sören, L.,
M. Nilsson, and L. E. Nilsson.
1995.
Quantitation of antibiotic effects on bacteria by bioluminescence, viable count and quantal analysis.
J. Antimicrob. Chemother.
35:669-674[Abstract/Free Full Text].
|
| 42.
|
Thore, A.,
S. Ånsehn,
A. Lundin, and S. Berman.
1975.
Detection of bacteriuria by luciferase assay of adenosine triphosphate.
J. Clin. Microbiol.
1:1-8[Abstract/Free Full Text].
|
| 43.
|
Versalovic, J.,
D. Shortridge,
K. Kimbler,
M. V. Griffy,
J. Beyer,
R. K. Flamm,
S. K. Tanaka,
D. Y. Graham, and M. F. Go.
1996.
Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.
Antimicrob. Agents Chemother.
40:477-480[Abstract].
|
| 44.
| Xia, H., M. Buckley, D. Hyde, C. T. Kaene, and
C. A. O'Morain. 1995. Effects of antibiotic-resistance on
clarithromycin-combined triple therapy for Helicobacter
pylori. Gut 37(Suppl. 1):A55. (Abstract
218.)
|
| 45.
|
Xia, H.,
M. Buckley,
C. T. Keane, and C. A. O'Morain.
1996.
Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro.
J. Antimicrob. Chemother.
37:473-481[Abstract/Free Full Text].
|
| 46.
|
Xia, H.,
M. A. Daw,
S. Sant,
S. Beattie,
C. T. Keane, and C. A. O'Morain.
1993.
Clinical efficacy of triple therapy in Helicobacter pylori-associated duodenal ulcer.
Eur. J. Gastroenterol. Hepatol.
5:141-144.
|
| 47.
|
Zwet, A. A.,
J. C. Thijs,
W. Schievink-de Vries,
J. Schiphuis, and J. A. M. Snijder.
1994.
In vitro studies on stability and development of metronidazole resistance in Helicobacter pylori.
Antimicrob. Agents Chemother.
38:360-362[Abstract/Free Full Text].
|
| 48.
|
Zwet, A. A.,
J. C. Thijs, and B. de Graaf.
1995.
Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains.
Antimicrob. Agents Chemother.
39:250-252[Abstract].
|
Antimicrobial Agents and Chemotherapy, May 1998, p. 1222-1228, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lui, S.-Y., Yeoh, K.-G., Ho, B.
(2003). Metronidazole-Resistant Helicobacter pylori Is More Prevalent in Patients with Nonulcer Dyspepsia than in Peptic Ulcer Patients in a Multiethnic Asian Population. J. Clin. Microbiol.
41: 5011-5014
[Abstract]
[Full Text]
-
Kobayashi, I., Muraoka, H., Saika, T., Nishida, M., Fujioka, T., Nasu, M.
(2001). Antimicrobial Susceptibilities of Helicobacter pylori Isolates under Microaerophilic Atmospheres Established by Two Different Methods. J. Clin. Microbiol.
39: 2646-2647
[Abstract]
[Full Text]
-
Paul, R., Postius, S., Melchers, K., Schäfer, K. P.
(2001). Mutations of the Helicobacter pylori Genes rdxA and pbp1 Cause Resistance against Metronidazole and Amoxicillin. Antimicrob. Agents Chemother.
45: 962-965
[Abstract]
[Full Text]
-
DeLoney, C. R., Schiller, N. L.
(2000). Characterization of an In Vitro-Selected Amoxicillin-Resistant Strain of Helicobacter pylori. Antimicrob. Agents Chemother.
44: 3368-3373
[Abstract]
[Full Text]
-
DeLoney, C. R., Schiller, N. L.
(1999). Competition of Various beta -Lactam Antibiotics for the Major Penicillin-Binding Proteins of Helicobacter pylori: Antibacterial Activity and Effects on Bacterial Morphology. Antimicrob. Agents Chemother.
43: 2702-2709
[Abstract]
[Full Text]
-
Han, S.-R., Bhakdi, S., Maeurer, M. J., Schneider, T., Gehring, S.
(1999). Stable and Unstable Amoxicillin Resistance in Helicobacter pylori: Should Antibiotic Resistance Testing Be Performed Prior to Eradication Therapy?. J. Clin. Microbiol.
37: 2740-2741
[Full Text]